Oculis (NASDAQ:OCS) Stock Price Up 8.3%

Oculis Holding AG (NASDAQ:OCS) shares were up 8.3% on Monday . The company traded as high as $13.16 and last traded at $13.02. Approximately 82,027 shares changed hands during trading, an increase of 74% from the average daily volume of 47,052 shares. The stock had previously closed at $12.02.

Analysts Set New Price Targets

A number of research analysts recently weighed in on OCS shares. Robert W. Baird lowered their target price on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Chardan Capital restated a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. HC Wainwright lowered their target price on shares of Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, April 24th. Finally, Wedbush restated an “outperform” rating and set a $29.00 target price on shares of Oculis in a research note on Wednesday, March 6th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Oculis presently has a consensus rating of “Buy” and a consensus price target of $29.14.

Oculis Stock Performance

The firm’s 50 day simple moving average is $11.85 and its 200 day simple moving average is $11.24. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.28 million. As a group, equities analysts expect that Oculis Holding AG will post -1.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in OCS. Wolverine Asset Management LLC purchased a new stake in shares of Oculis in the 3rd quarter worth approximately $77,000. Searle & CO. purchased a new position in shares of Oculis in the fourth quarter worth $112,000. Compagnie Lombard Odier SCmA raised its holdings in shares of Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after buying an additional 30,750 shares during the last quarter. Finally, abrdn plc acquired a new stake in shares of Oculis in the fourth quarter worth $15,980,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.